UUÂãÁÄÖ±²¥

Legal News

Teva fined €462.6m for artificially extending patent protection of Copaxone

Published on: 01 November 2024
Published by LNB News

LNB News 01/11/2024

Document Information

Issue Date: 01 November 2024

Published Date: 01 November 2024

Jurisdiction(s): European Union

Article summary

The European Commission has fined Teva €462.6m after it found that it abused its dominant position to delay competing products to its treatment for multiple sclerosis, Copaxone, entering the market. The pharmaceutical company artificially extended the patent protection for Copaxone by misusing the European Patent Office’s rules and procedures on divisional patents, and systematically spread misleading information about a competing and cheaper product’s safety, efficacy and therapeutic equivalence with Copaxone in order to hinder market entry and uptake. The Commission decided that Teva’s abuses were complementary and together amounted to a single and continuous infringement of Article 102 TFEU.

Popular documents